ViaDerma, Inc.

Equities

VDRM

US92555K1016

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 09:35:16 2024-04-29 am EDT			5-day change	1st Jan Change
0.0096 ^USD	-4.00%		-1.03%	-9.43%

2023	ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	CI
2023	ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	CI

ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product

March 16, 2023 at 08:00 am EDT

ViaDerma, Inc. announced that the company has recently submitted their application for their planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and expect this process to be completed within a few weeks. The company has chosen Nupelo as the brand name for its new hair regrowth product.

Nupelo will incorporate ViaDerrma's proprietary, patent-pending dual carrier transdermal delivery technology and use Minoxidil (topical route) in their new hair regrowth product. ViaDerma plans to make Nupelo available for purchase via several online platforms including their newly acquired domain, nupelo.com. The product is expected to be ready to go to market and available to purchase online by the end of Second Quarter 2023.

Latest news about ViaDerma, Inc.

ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	23-03-16	CI
ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	23-03-08	CI
ViaDerma, Inc. Successfully Completes Quality Control Testing of Its New Vitastem Products	22-09-15	CI
ViaDerma, Inc. Set to Launch Two New and Improved Versions of Its Flagship Product, Vitastem and Vitastem Ultra	21-10-04	CI
ViaDerma, Inc. Provides Updates on Current Business Activities	21-06-24	CI
ViaDerma, Inc. Announces Expansion of Its Current Licensing Agreement	21-06-02	CI
ViaDerma, Inc. Nearing Initial Order from Large Hospital Network	21-05-13	CI
ViaDerma, Inc. Provides Revenue Guidance for the First Quarter of 2021	21-04-08	CI
ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States	21-01-21	CI
ViaDerma, Inc. Enters into A $250,000 Initial Sales Agreement with Vage Nigeria Ltd	18-04-24	CI
ViaDerma, Inc. Grants Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products	17-11-21	CI
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx	17-10-19	CI
ViaDerma, Inc. Receives National Drug Code from the FDA for Prolayed	17-06-27	CI
Viaderma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and Development of New Products with its MMJ Technologies	17-05-15	CI
Viaderma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration for New OTC Drug to Conquer Premature Ejaculation for Men	17-04-05	CI
ViaDerma, Inc. Hires Ivan Klarich to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch	17-03-08	CI
ViaDerma, Inc. Signs Licensing and Distribution Agreement with Two Pharmaceuticals Companies for its FDA Registered Drug	17-01-11	CI
ViaDerma, Inc. Announces Preston Richards to Join Advisory Board	15-01-22	CI
ViaDerma, Inc. Announces TetraStem	14-12-09	CI
ViaDerma, Inc. Appoints Dr. Andrew Berman as Medical Director of Advisory Board	14-11-13	CI
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA	14-10-30	CI
Décor Products International, Inc. will Change its Name to ViaDerma, Inc	14-05-06	CI

Chart ViaDerma, Inc.

Duration

Period

More charts

Company Profile

ViaDerma, Inc. is a specialty pharmaceutical company engaged in bringing new products to market and licensing its transdermal drug delivery technology solutions. The Companyâs lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. In addition to licensing its proprietary transdermal technologies, its lead product, Vitastem, is available for treating multiple skin conditions and ailments. The Company also has products in development in fields, such as anti-aging skin care, pain management, hair-loss, and toenail fungus. The products are based on a delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The Companyâs products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Companyâs subsidiary is ViaDerma, II Inc.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIADERMA, INC.	-9.43%	12.34M
IQVIA HOLDINGS INC.	+2.21%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+11.32%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.90%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.72%	18.12B
MEDPACE HOLDINGS, INC.	+29.58%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.99%	11.76B
UNITED THERAPEUTICS CORPORATION	+7.88%	11B

Other Biotechnology & Medical Research